Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Los términos de búsqueda han de ser en inglés.

Pequeño dispositivo electrónico para hacer un seguimiento del tratamiento de la diabetes

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20160406001
Publicado:
08/04/2016
Caducidad:
08/04/2017
Resumen:
Una pyme española especializada en tecnologías de e-salud ha desarrollado un pequeño dispositivo electrónico que se conecta fácilmente a cualquier pluma de insulina para ayudar a los pacientes a hacer un seguimiento automático de la información crítica de su tratamiento, como recordar fechas, hora y dosis de la última inyección y el momento de ponerse la siguiente. El dispositivo electrónico envía la información, mediante Bluetooth, a una aplicación preinstalada, guardando los datos en la nube para su almacenamiento y sincronización con múltiples dispositivos. Se buscan empresas de la industria farmacéutica y médica con el fin de establecer acuerdos comerciales con asistencia técnica.

Details

Tittle:
Small electronic device for tracking Diabetes treatment
Summary:
A Spanish SME has developed a small electronic device very easily plugged in any insulin injection pen, which helps patients automatically track critical information about their treatment, such as remembering the date, time and dosage of the last shot and the time of the next one. The SME is willing to sign a commercial agreement with technical assistance with companies from the pharmaceutical and health sector.
Description:
A Spanish start-up company focused on e-health technologies provides an efficient solution for diabetic patients through a device that helps to manage the right administration of insulin in a controlled manner by an automatic tracking of critical information about the treatment, such as dates, times and dosages of the last shot. The technology consists in a small electronic device that is easily connected to any insulin injection pen and that sends, via Bluetooth, the information to a pre-installed app, keeping data in the Cloud for data warehouse and synchronization with multiple devices. The app helps diabetics and their doctors and caregivers to manage the disease along time.

Most relevant features:
- Mechanical resistance of the device.
- Redundancy-based reliability (data stored at both the device and the app).
- Usability of the app. iOS and Android devices being covered.
- Universality: it adjusts to any insulin pen.
- Small size, small weight.
- Long term duration of batteries (more than a year).
- Battery can be changed.

The SME would like to find companies from the pharmaceutical and health sector interested in signing a commercial agreement with technical assistance that would arrange the acquisition of the system paired with the provision of technical assistance in engineering and technical consultancy.
Advantages and Innovations:
Main advantages for users:
- First wearable for the insulin pen. It allows an optimal follow up of the treatment and brings significant progress if compared to its competitors, since none of them connect the insulin pen with our mobile or send data to the Cloud to have a statistical control of medication
- Integrated in treatment routine. It has been designed to compile required data automatically, so that patients do not really need to do anything else but carry on their treatment. Security does not longer depend on the scrupulosity of patients.
- Data requirements and alert systems have been adjusted to real and critical needs of diabetics (no more, no less), also considering the needs of their caregivers (for the first time).
- Temperature sensor included to assure the correct conservation of the insulin.
Main advantages for pharmaceutical, health insurer and healthcare provider companies:
- They can measure the adherence to treatment and this enables them to insure persons with diabetes, perform risk-shared agreements with pharmaceutical companies and give a better service to their clients.
- They are interested in the data generated by the device to know the habits of their consumers.
- It enables the possibility to implement a telemedicine system where physicians can monitor their patients more effectively: seeing in real time incidences and finding the ones with worse control to call and offer them support. The automatically generated data are more reliable, so the calculations performed by the physicians will be more useful.
Main benefits:
- Increased security and quality of life with no extra burden for patients.
- Self-control of the disease and empowerment.
- Support to caregivers for remotely monitoring and managing treatment.
- New business models for pharmaceutical and health insurance companies
- Better treatment of people with diabetes thanks to the telemedicine system
- Cost saving for healthcare providers
Stage of Development:
Available for demonstration
IPs:
Secret Know-how,Design Rights,Patent(s) applied for but not yet granted,Trade Marks,Exclusive Rights,Copyright,Other
CommeR Statunts Regarding IPR Status:
Spanish patent and European Industrial design granted. European patent pending.

Partner sought

Type and Role of Partner Sought:
The SME would like to find companies from the pharmaceutical and health sector interested in signing a commercial agreement with technical assistance that would arrange the acquisition of the system paired with the provision of technical assistance in engineering and technical consultancy.

Client

Type and Size of Client:
Industry SME <= 10
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06001015 Productos farmacéuticos / medicamentos
06001013 Tecnología médica / ingeniería biomédica